Who are Staloral 300's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): tree 12 SQ-Bet, HDM 12 SQ-HDM, ALK Grass tablet, Tree SLIT-tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/staloral-300.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Staloral 300 — Competitive Intelligence Brief

Staloral 300 (Staloral 300) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allergen immunotherapy (sublingual tablet). Area: Immunology / Allergy.

marketed Allergen immunotherapy (sublingual tablet) Grass pollen allergens (Phleum pratense and related species) Immunology / Allergy Small molecule Live · refreshed every 30 min

Target snapshot

Staloral 300 (Staloral 300) — Medical University of Lodz. Staloral 300 is an allergen immunotherapy that desensitizes the immune system to grass pollen allergens through sublingual administration.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Staloral 300 TARGET	Staloral 300	Medical University of Lodz	marketed	Allergen immunotherapy (sublingual tablet)	Grass pollen allergens (Phleum pratense and related species)
tree 12 SQ-Bet	tree 12 SQ-Bet	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy (sublingual tablet)	Tree pollen allergens (IgE cross-linking epitopes)
HDM 12 SQ-HDM	HDM 12 SQ-HDM	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy (sublingual tablet)	House dust mite allergens (Der p 1, Der p 2, Der f 1, Der f 2)
ALK Grass tablet	ALK Grass tablet	ALK-Abelló A/S	phase 3	Allergen immunotherapy (sublingual tablet)	Grass pollen allergens (multiple epitopes)
Tree SLIT-tablet	Tree SLIT-tablet	ALK-Abelló A/S	phase 3	Allergen immunotherapy (sublingual tablet)	Tree pollen allergen epitopes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allergen immunotherapy (sublingual tablet) class)

ALK-Abelló A/S · 2 drugs in this class
Clinique Spécialisée en Allergies de la Capitale · 2 drugs in this class
Medical University of Lodz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Staloral 300 — Competitive Intelligence Brief. https://druglandscape.com/ci/staloral-300. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab